teaser
Novartis announced today new data, including a late breaking presentation on Tasigna (nilotinib) in a form of chronic myeloid leukemia
The new data, at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition, highlight the company’s current therapies and investigational agents in 195 studies including 39 oral presentations.
Data will be presented on Tasigna, Afinitor (everolimus) tablets, Exjade (deferasirox) and pipeline agents including PKC412 (midostaurin), LBH589 (panobinostat), BHQ880 and INCB18424, an oral, selective Janus kinase (JAK) inhibitor that was recently added to the oncology pipeline through a licensing agreement.
“Data presented at ASH will demonstrate the vigorous research underway to explore the best treatment approaches for patients with rare blood cancers and conditions,” said David Epstein, President and CEO, Novartis Oncology and Novartis Molecular Diagnostics.
“We expect these data to lay the groundwork for regulatory submissions and provide a roadmap for the initiation of late-stage and pivotal trials.”
The ASH Annual Meeting will feature results from a pivotal head-to-head study comparing the efficacy and safety of Tasigna versus Glivec (imatinib)* in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) in chronic phase (Abstract #LBA-1; Tuesday, December 8, 2009 at 7:30 AM CST).
Data from this Phase III clinical trial, ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+ CML Patients), will show that Tasigna produced faster and deeper responses than Glivec when used as first-line therapy.
